RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma Ltd. has announced the issuance of a new Chinese patent for opaganib, in combination with immune checkpoint inhibitors, to induce an anti-cancer immune response, with protection extending through 2040. This patent strengthens the company’s portfolio and supports its efforts in cancer treatment, where the global market for immune checkpoint inhibitors is forecasted to surpass $100 billion by 2028. Opaganib, a versatile oral medication, is also being developed for various diseases, including COVID-19 and Ebola, and has been selected for U.S. government countermeasure programs addressing Acute Radiation Syndrome and Sulfur Mustard exposure.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
